Drug Profile
CTP 010
Alternative Names: CTP-010Latest Information Update: 27 May 2015
Price :
$50
*
At a glance
- Originator Concit Pharma
- Developer Contera Pharma
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Phase Unknown Drug-induced dyskinesia
Most Recent Events
- 24 Apr 2013 Investigation in Drug-induced dyskinesia in Denmark (unspecified route)
- 24 Apr 2013 Concit Pharma plans a phase IIa trial for Drug-induced dyskinesia